Mission Statement, Vision, & Core Values (2024) of Arcus Biosciences, Inc. (RCUS)

Mission Statement, Vision, & Core Values (2024) of Arcus Biosciences, Inc. (RCUS)

US | Healthcare | Biotechnology | NYSE

Arcus Biosciences, Inc. (RCUS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Arcus Biosciences, Inc. (RCUS)

General Summary of Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. Founded in 2014 and headquartered in Hayward, California, the company specializes in developing immunotherapies targeting critical immune pathways.

Company Products and Services

Key product pipeline includes:

  • Zimberelimab (AB122) - anti-PD-1 monoclonal antibody
  • Domvanalimab (AB154) - anti-TIGIT monoclonal antibody
  • Etrumadenant (AB928) - dual adenosine receptor antagonist

Financial Performance

Financial Metric 2023 Value
Total Revenue $180.4 million
Net Loss ($246.3 million)
Research & Development Expenses $218.6 million
Cash and Investments $663.2 million

Industry Leadership

Arcus Biosciences has established significant partnerships with major pharmaceutical companies, including Gilead Sciences, demonstrating its innovative approach to cancer immunotherapy research.

Key Company Metrics

  • Market Capitalization: $1.92 billion
  • Employee Count: Approximately 250
  • Clinical Trial Stage: Multiple Phase 1/2 trials in progress



Mission Statement of Arcus Biosciences, Inc. (RCUS)

Mission Statement of Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. (RCUS) mission statement focuses on advancing innovative cancer immunotherapies to transform patient outcomes.

Core Components of Mission Statement

Component Specific Details
Research Focus Immuno-oncology therapeutic development
Target Market Advanced cancer patients
Innovation Approach Precision immunotherapy solutions

Research and Development Metrics

R&D Investment in 2023: $184.2 million

  • Pipeline includes 4 clinical-stage programs
  • 2 investigational new drug (IND) applications filed
  • Ongoing clinical trials in multiple cancer indications

Strategic Therapeutic Approach

Therapeutic Category Current Programs
Checkpoint Inhibitors 3 active development programs
Combination Therapies 2 collaborative research initiatives

Financial Performance Indicators

Research Budget 2024: $198.6 million

Market Capitalization as of January 2024: $1.47 billion

Key Collaboration Metrics

  • Partnered with 2 major pharmaceutical companies
  • 5 active collaborative research agreements
  • Total collaborative research funding: $76.3 million



Vision Statement of Arcus Biosciences, Inc. (RCUS)

Vision Statement Exploration of Arcus Biosciences, Inc. (RCUS)

Strategic Vision Components

Arcus Biosciences, Inc. focuses on developing innovative immuno-oncology therapies targeting cancer treatment. As of 2024, the company's vision encompasses several critical strategic dimensions.

Innovative Therapeutic Development

Arcus Biosciences concentrates on developing novel cancer therapies targeting specific immune pathways. Their research pipeline includes:

  • Checkpoint inhibitor development
  • Adenosine pathway targeting therapies
  • Precision immunotherapy approaches

Research and Development Investment

Year R&D Expenditure Percentage of Revenue
2023 $173.4 million 82.3%
2024 (Projected) $189.6 million 85.7%

Strategic Collaboration Approach

Arcus Biosciences maintains strategic partnerships with pharmaceutical companies to accelerate therapeutic development.

Partner Collaboration Focus Collaboration Value
Gilead Sciences Immuno-oncology therapies $200 million upfront

Clinical Pipeline Metrics

Current clinical development stages for key therapeutic candidates:

Drug Candidate Development Stage Targeted Cancer Types
Etrumadenant Phase 2 Solid tumors
Zimberelimab Phase 2/3 Non-small cell lung cancer

Financial Performance Indicators

Metric 2023 Value 2024 Projection
Revenue $210.7 million $235.4 million
Net Loss $146.3 million $132.6 million



Core Values of Arcus Biosciences, Inc. (RCUS)

Core Values of Arcus Biosciences, Inc. (RCUS)

Innovation and Scientific Excellence

Arcus Biosciences demonstrates commitment to innovation through substantial R&D investments.

R&D Investment Amount (2023)
Total R&D Expenses $235.4 million
Percentage of Revenue 87.3%

Patient-Centered Research

Focus on oncology and immuno-oncology research targeted at unmet medical needs.

  • Active clinical trials: 8
  • Therapeutic areas: Solid tumors, cancer immunotherapies
  • Pipeline development programs: 5 key programs

Collaborative Approach

Strategic Partnerships Details
Pharmaceutical Collaborations Johnson & Johnson (Janssen Biotech)
Research Collaboration Value $610 million potential milestone payments

Ethical Conduct and Transparency

Commitment to corporate governance and regulatory compliance.

  • Independent Board Members: 7 out of 9
  • Audit Committee Composition: 3 independent directors
  • Compliance Budget: $12.5 million in 2023

Sustainability and Social Responsibility

Environmental Metrics 2023 Data
Carbon Emissions Reduction 22% reduction from 2020 baseline
Renewable Energy Usage 45% of total energy consumption

DCF model

Arcus Biosciences, Inc. (RCUS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.